Business · 27/12/2023Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for SCEMBLIX Patent Extension
Summary
The FDA has published a notice determining the regulatory review period for SCEMBLIX, a human drug product, following a submission to the USPTO for patent extension.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →